HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Califf Pledges To Counter Misinformation As He Returns To US FDA Helm

Executive Summary

FDA commissioner's commitment to counter misinformation also appears to include pledge to ensure agency is driven by science-based decisions, not politics.

You may also be interested in...



DoJ's COVID-19 Fraud Enforcement Gets A Director

Associate Deputy Attorney General Kevin Chambers oversees DoJ’s enforcement and prosecution of COVID-19 criminal and civil fraud.

Dr. Califf Returns To US FDA: What To Do First?

Acting commissioner Janet Woodcock will remain at the agency and become principal deputy commissioner when Califf arrives.

Florida Versus US FDA ... Again

The very public attempt by the state of Florida to question FDA’s decision on COVID monoclonal antibodies is the latest example of how the politics of COVID is roiling the agency’s reputation. But is it really so different than Florida’s pre-pandemic plans to import drugs from Canada?

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS152231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel